Literature DB >> 19210958

Regulation by 1, 25-dihydroxy-vitamin D3 on altered TLRs expression and response to ligands of monocyte from autoimmune diabetes.

Tao Du1, Zhi-Guang Zhou, Shuo You, Jian Lin, Lin Yang, Wei-Dong Zhou, Gan Huang, Chen Chao.   

Abstract

BACKGROUND: Altered Toll-like receptors (TLRs) expression and response of monocyte may be associated with insulin sensitivity, obesity and diabetes.
METHODS: Peripheral blood monocytes were respectively collected from 23 healthy controls, 16 type 1 diabetes mellitus (T1DM), and 18 latent autoimmune diabetes in adults (LADA). CD14, TLR2 and TLR4 expression were analyzed by flow cytometer. Moreover, the effect of 1, 25-dihydroxy-vitamin D3 (1,25(OH)(2)D3) on monocyte response to lipoteichoic acid (LTA) and lipopolysaccharide (LPS) was evaluated in vitro by measuring phosphorylation concentration of NF-kappaB-p65 and associated cytokine production.
RESULTS: Monocytes showed significantly higher surface CD14 and TLR4 expressions from LADA and lower CD14 expression from T1DM than controls. TLRs ligands decreased monocyte CD14 expression in T1DM but increased in LADA. Monocyte hyperresponsiveness to ligands was modulated by 1,25(OH)(2)D3 to similar concentration, as compared to controls.
CONCLUSIONS: Monocytes from T1DM and LADA showed similar cellular reactivity towards ligands and 1,25(OH)2D3 was observed to restore this defect to a certain extent in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210958     DOI: 10.1016/j.cca.2008.12.038

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications.

Authors:  Ishwarlal Jialal; Harmeet Kaur
Journal:  Curr Diab Rep       Date:  2012-02-08       Impact factor: 4.810

Review 2.  Epigenetic regulation of Toll-like receptors and its roles in type 1 diabetes.

Authors:  Zhiguo Xie; Gan Huang; Zhen Wang; Shuoming Luo; Peilin Zheng; Zhiguang Zhou
Journal:  J Mol Med (Berl)       Date:  2018-07-12       Impact factor: 4.599

3.  Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions.

Authors:  Agnieszka Jezierska; Irina A Kolosova; Alexander D Verin
Journal:  Curr Signal Transduct Ther       Date:  2011

Review 4.  Vitamin D insufficiency and insulin resistance in obese adolescents.

Authors:  Catherine A Peterson; Aneesh K Tosh; Anthony M Belenchia
Journal:  Ther Adv Endocrinol Metab       Date:  2014-12       Impact factor: 3.565

5.  Vitamin D treatment modulates organic dust-induced cellular and airway inflammatory consequences.

Authors:  Gregory A Golden; Todd A Wyatt; Debra J Romberger; Daniel Reiff; Michael McCaskill; Christopher Bauer; Angela M Gleason; Jill A Poole
Journal:  J Biochem Mol Toxicol       Date:  2012-12-20       Impact factor: 3.642

6.  microRNA-143-3p contributes to inflammatory reactions by targeting FOSL2 in PBMCs from patients with autoimmune diabetes mellitus.

Authors:  Shan Pan; Mengyu Li; Haibo Yu; Zhiguo Xie; Xia Li; Xianlan Duan; Gan Huang; Zhiguang Zhou
Journal:  Acta Diabetol       Date:  2020-08-20       Impact factor: 4.280

Review 7.  Vitamin D in physiological and pathological aging: Lesson from centenarians.

Authors:  Evelyn Ferri; Martina Casati; Matteo Cesari; Giovanni Vitale; Beatrice Arosio
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 8.  Innate immunity in latent autoimmune diabetes in adults.

Authors:  Juan Huang; James Alexander Pearson; F Susan Wong; Li Wen; Zhiguang Zhou
Journal:  Diabetes Metab Res Rev       Date:  2021-06-22       Impact factor: 4.876

9.  Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies.

Authors:  Maeve A McArdle; Orla M Finucane; Ruth M Connaughton; Aoibheann M McMorrow; Helen M Roche
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-10       Impact factor: 5.555

10.  1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.

Authors:  Yasuteru Kondo; Takanobu Kato; Osamu Kimura; Tomoaki Iwata; Masashi Ninomiya; Eiji Kakazu; Masahito Miura; Takehiro Akahane; Yutaka Miyazaki; Tomoo Kobayashi; Motoyasu Ishii; Norihiro Kisara; Kumiko Sasaki; Haruo Nakayama; Takehiko Igarashi; Noriyuki Obara; Yoshiyuki Ueno; Tatsuki Morosawa; Tooru Shimosegawa
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.